At the heart of the discipline sit synthetic genetic circuits, which the authors describe as the basic building blocks of the entire enterprise. These circuits control the production, turnover or depletion of specific DNA, RNA or protein molecules, giving researchers programmable control over gene expression and cellular behavior. The repertoire includes logic gates that mirror digital electronics, with BUFFER, NOT, AND, OR, XOR, NAND, NOR and XNOR configurations each activating or repressing output genes under distinct input conditions. Oscillators generate rhythmic fluctuations in protein concentrations, echoing natural circadian clocks and cell cycle regulators, while toggle switches act as biological memory, holding gene expression stably on or off much like flip-flop circuits in electronics. The landmark repressilator built by Elowitz and Leibler in Escherichia coli, a ring of three repressor proteins that suppress one another in sequence, produced green fluorescent protein oscillations with a period of roughly 150 minutes, about three times longer than the cell division cycle, demonstrating that entirely artificial networks could function robustly inside living bacteria.

The clinical implications of these circuits are already substantial. Genetic switches integrated into human cells can detect internal disease signals and respond with closed-loop logic, or react to external molecular cues in an open-loop configuration. When such circuits are built into next-generation chimeric antigen receptor T cells, they allow precise control over the timing and intensity of immune responses, improving both safety and effectiveness. A study by Daniels and colleagues designed more than 1,200 receptors combining twelve different signaling motifs and, using machine learning, identified synthetic motifs absent from natural receptors that created new T cell phenotypes with enhanced antitumor efficacy. In parallel, Li and colleagues developed synthetic zinc finger transcription factors, called synZiFTRs, that target an artificial 18-base-pair promoter not found in the human genome. Their activity could be controlled with three FDA-approved drugs: the antiviral grazoprevir induced anti-HER2 CAR expression in T cells, while tamoxifen triggered production of super high-affinity IL-2, producing drug-controllable antitumor effects in mouse models of NALM6 leukemia.

Synthetic chromosomes represent an even bolder frontier. Jason Chin’s team synthesized the entire E. coli genome, roughly four times larger than any previously synthesized genome, and compressed its genetic code from 64 to 61 codons by recoding 18,214 codon instances, using the REXER method to progressively replace the native genome with the synthetic version across eight parallel strains that were then combined by conjugation. In eukaryotes, the Sc2.0 Synthetic Yeast Genome Project, led by Jef Boeke of Johns Hopkins University, aims to build a designer genome for Saccharomyces cerevisiae, a organism with roughly 6,000 genes. Its signature SCRaMbLE system embeds more than 5,000 loxP recombination sites that can be rapidly activated to shuffle genetic content, generating millions of cell variants from which strains with improved industrial traits can be selected. After ten years of intensive work, an international collaboration spanning the UK, USA, China, Singapore, France and Australia completed synthetic chromosome XI, a 660,000-base-pair sequence that replaced a natural yeast chromosome while preserving normal cellular fitness through rigorous error correction.

Metabolic engineering, a discipline that emerged in the 1990s, is delivering some of the field’s most tangible products. Jay Keasling’s team engineered Saccharomyces cerevisiae to produce artemisinic acid, the precursor to the antimalarial drug artemisinin, by inserting and optimizing genes from multiple organisms including the malaria parasite Plasmodium falciparum, creating a sustainable fermentation route that sidesteps the variability of plant extraction. Lee and colleagues achieved something once thought impossible: engineered E. coli producing 1,4-butanediol, an industrial chemical made in more than 2.5 million tons annually that no living organism produces naturally, at a yield of 18 grams per liter from renewable sugars including glucose, xylose and sucrose. On the energy front, Nielsen and colleagues developed three microbial platforms, based on Saccharomyces cerevisiae, Zymomonas mobilis and E. coli, capable of fermenting lignocellulose sugars into bioethanol, though the authors note that competitive production will require optimization across every stage of the process. Dynamic metabolic control has also matured: by rewiring the transcriptional regulator FapR to balance malonyl-CoA supply and consumption in E. coli, researchers achieved a 15.7-fold improvement in fatty acid production.

The tools that make all of this possible have themselves undergone a quiet revolution. Standardized cloning remains foundational, with plasmids carrying replication origins, selection markers and promoters serving as the workhorses of gene transfer, and modular systems such as SureVector accelerating vector assembly. BioBrick standard parts, stored in the Standard Biological Parts Registry and central to the international iGEM competition, embody the field’s commitment to abstraction and interchangeability. Gibson assembly allows multiple DNA fragments with homologous overlapping ends to be joined seamlessly in an hour or less without restriction enzymes, while Golden Gate assembly and its extensions, including MoClo and Golden Braid, use type IIS enzymes to combine many fragments in a single tube. De novo DNA synthesis now delivers designed sequences within days or weeks, though cost and accuracy remain limiting factors. Perhaps most conceptually important is the chassis: researchers at the J. Craig Venter Institute, starting from Mycoplasma genitalium, progressively defined a minimal cell, and by 2016 produced a organism with just 473 genes across 531 kilobase pairs, a simplified biological platform that minimizes interference with engineered circuits.

Beyond cancer, the review documents synthetic biology’s reach into diagnostics, tissue engineering and drug delivery. Engineered E. coli that produce LacZ upon contacting tumor cells can detect tumors smaller than one centimeter through a simple urine luminescence test, while Salmonella enterica colonizing tumor tissue can convert a prodrug into 5-fluorouracil that eradicates cancer cells. In tissue engineering, synthetic circuits built on Tet-on and Tet-off systems allow temporally controlled expression of genes such as Runx2 and Sox9, guiding bone and cartilage formation in implanted scaffolds, and biomaterial-encased gene switches have sustained reporter expression for more than 300 days in some systems. Bottom-up synthetic cells are emerging as drug carriers: Chen and colleagues built synthetic beta cells from multi-compartment vesicles containing glucose oxidase, catalase and insulin-loaded liposomes that released insulin in response to glucose and normalized blood sugar in type 1 diabetic mice, while other synthetic cells producing Pseudomonas exotoxin A killed cancer cells more effectively than purified toxin alone.

Biosensors and anti-infective therapies round out the medical portfolio. The ROSALIND platform developed by Collins and colleagues uses cell-free, freeze-dried reactions with allosteric transcription factors to detect 16 different water contaminants, producing visible RNA-based signals that can be shipped at ambient temperature and deployed in field tests on municipal water. Against antibiotic resistance, engineered phages have shown striking results: a T7 phage producing the biofilm-degrading enzyme dispersin B eliminated 99.997 percent of bacteria within a biofilm, and a lytic M13 phage suppressing bacterial DNA damage responses significantly enhanced the killing of resistant cells by existing antibiotics. Phage display technology, pioneered by George Smith and applied to antibodies by Gregory Winter, underlies drugs such as adalimumab for rheumatoid arthritis, and AI tools like AlphaFold are now accelerating therapeutic antibody design by modeling binding sites with unprecedented speed and accuracy.

Agriculture and industry complete the picture, alongside sobering warnings. Pivot Bio’s engineered nitrogen-fixing bacteria increased corn yields by 5.8 bushels per acre while cutting chemical fertilizer use by 25 pounds per acre, without the greenhouse gas emissions and runoff of conventional fertilizers. CRISPR/Cas9 editing has boosted GABA content in tomatoes seven- to fifteen-fold, raised lycopene levels 5.1-fold through multiplex editing, and enabled de novo domestication of allotetraploid wild rice by Jiayang Li’s team. Even de-extinction has entered the agenda, with George Church’s project aiming to modify around 45 genes in the Asian elephant genome to create a cold-tolerant, mammoth-like hybrid. Yet the authors close with a caution: the same tools that promise sustainable fuels and personalized medicines could, through accident or intent, produce harmful biological agents, and they argue that strong biosafety and biosecurity policies at national and global levels are a critical precondition for safely delivering synthetic biology’s benefits to society. By 2030, they predict, most people will use a product built by this technology, whether they know it or not.

Subject of Research: Applications of synthetic biology in medicine, agriculture and industry

Article Title: Synthetic biology and application areas

Article References: Karataş, P., & Ayaz, F. (2025). Synthetic biology and application areas. Discover Biotechnology, 2(1), Article 3. https://doi.org/10.1007/s44340-025-00010-5

Image Credits: AI Generated

DOI: 10.1007/s44340-025-00010-5

Keywords: synthetic biology, genetic circuits, CAR-T cell therapy, synthetic chromosomes, metabolic engineering, CRISPR, biosensors, drug delivery, biofuels, Sc2.0 yeast genome, repressilator, biosecurity